IPM
Time to buy pharma? 3 stocks Forum Parekh is betting on
Zydus Life's US business is going to report a good set of numbers. Also, in India, wellness products are doing good, Overall Zydus Life will tend to report some 25% EBITDA margin. Therefore, Sharekhan By BNP Paribas has a buy call on Zydus Life with a price target of almost Rs 1200, says Foram Parekh
Kotak Equities initiates coverage on JB Chemicals with a target price of Rs 2,025
“Having primarily grown organically until FY2022 and later on aided by benefits from acquired brands, JB has handsomely outperformed the IPM in the past decade by ~600 bps and currently ranks 22 in the IPM,” said Alankar Garude, Analyst at Kotak Equities.
Taller, stronger, sharper: Desi pharma is on a roll
The Avendus Capital report attributed the eye-catching growth of large Indian pharma brands to lifestyle diseases, prevalent quality issues that made doctors and customers rely more on big, well-known brands, along with aggressive sales and marketing push by pharma companies.
Torrent Pharma board approves to raise Rs 5,000 crore
Torrent Pharmaceuticals, actively seeking to expand through acquisitions, has expressed interest in purchasing Mumbai-based pharmaceutical company JB Pharma, according to a report by ET on Friday.
Heatwave ignites surge in chronic therapy demand
Rising temperatures across various regions of India are driving increased demand for medications aimed at managing chronic conditions. This includes prescriptions for high blood pressure (antihypertensives), cholesterol (lipid-lowering drugs), and blood clotting (platelet aggregation inhibitors).
Drone-based agritech startup BharatRohan raises $2 million
BharatRohan, a startup, raised $2.3 million pre-IPO for developing advanced drones for crop monitoring. The fund will expand services nationwide, supporting 50,000 farmers across five states with hyperspectral sensors for precise agricultural insights.
- Go To Page 1
Indian pharma market posts robust 9.5% growth in March
India's pharmaceutical market saw a 9.5% growth in March, reaching '16,158 crore in sales. The Moving Annual Total reached '197,976 crore with a 6.5% growth rate, with cardiology and anti-infectives among the top performers.
Pharma market grows 9.5% in January
The Indian pharmaceutical market (IPM) saw a robust growth of 9.5% in January with all major therapy areas recording double-digit growth. According to market research firm Pharmarack, a majority of the top 10 therapy areas, including cardiac, anti-infectives, and gastrointestinal, showed double-digit value growth. Respiratory, pain/analgesics, urology, antineoplastics, and stomatologicals also saw higher unit growth.
JB Pharma Q3 Results: Net profit jumps 26% to Rs 134 crore
The drug maker had reported a net profit of Rs 106 crore in the year-ago period. Revenue for the quarter rose 7% YoY to Rs 845 crore The Mumbai-based company reported operating earnings before interest, taxes, depreciation and amortisation (EBITDA) at Rs 235 crore, up from Rs 193 crore in the year-ago period.
Delhi-based start-up Indo Petroleum Marketing begins pan-India ops from Assam
Delhi-based start-up Indo Petroleum Marketing (IPM) has begun its pan-India operations in Assam after being granted fuel retail marketing authorization by the Ministry of Petroleum and Natural Gas. IPM aims to set up five outlets in rural areas of Assam and plans to establish petrol pumps nationwide. This makes IPM the first Ministry-authorized start-up private oil marketing company (OMC) to begin operations.
Philip Morris International’s India affiliate appoints Navaneel Kar as managing director
Navaneel Kar has been appointed as the managing director of Philip Morris International Indian operations, IPM India. Prior to this role, he served as the president of sales at Tata Consumer Products. Kar will report to Ankur Modi, Cluster Head, South Asia & IndoChina, PMI.
Startup IPM to set up 100 fuel outlets; to start from Assam
The Delhi-based company has already generated a net worth of Rs 250 crore to roll out its network to sell different types of fuel in the country.
Pharma growth shrinks to 4.5% in June as Covid-led segments show decrease in sales
India's pharmaceutical market contracted by 4.5% in June due to a fall in anti-infectives and respiratory drug sales as Covid cases decreased. According to an IQVIA report, the Moving Annual Turnover (MAT) growth for June fell to 10.6% from 11.3% in May. The highest growth therapies were anti-viral, antineoplast/immunomodulator, urology and vaccines. The report also shows a higher growth rate for the chronic segment than the acute segment. Sandeep Budhiraja of Max Healthcare noted that they are seeing a relatively mild flu season, which is occurring earlier than usual.
Pharma Industry staring at 30-40 bps hit on updated NLEM
Manchanda added that the anti-infectives treating HIV, TB and drug cessation treatments in the list doesn't have a major impact on margins as they are mostly procured by the government through tenders. There are potential beneficiaries also with the new NLEM. The removal of antacid molecule ranitidine which has more than Rs 600 crore annual sales is expected to benefit JB Pharma and Cadila Pharmaceuticals.
Indian pharma market grew 12.1% in August, AWACS report
The wholesale price index (WPI) inflation linked price hike allowed by the government has helped the pharma industry to increase by 10% on drugs under price control, along with monsoon linked infectious diseases. The fastest growing categories are cardiac which grew at 13%, anti-infectives - 13% and gastrointestinal - 12%. Anti-diabetes and vitamins grew 9% respectively.
Traditional agri-chemical companies bet big on bio-solutions market
Torretta said that for NPP products, UPL is seeing demand from farmers due to their concern on plant growth & stress, soil health and need for sustainable solutions. Other key demand-driving factors are from the organic product and export segment which has additional pain points such as residue management that are also addressed by NPP products.
India's pharma sector growth accelerates in May due to low base effect
The ratings agency opined that the 47.8 per cent YoY growth in India's pharmaceutical market (IPM) during May 2021 was led by a low base effect.
Less than four percent Indian farmers adopted sustainable agricultural practices, says study
The study, supported by the Food and Land Use Coalition (FOLU), found that scaling up sustainable agriculture would be critical to improve farm incomes and bolster India's nutrition security in a climate-constrained future. States such as Andhra Pradesh and Sikkim have already taken a lead in sustainable agriculture.
Bucking the pandemic: India's on its way to become the world's pharmaceutical hub
Consequently, the Centre's new-found vision amid the Covid-19 pandemic for a self-reliant India -- 'Aatmairbhar Bharat' -- if accomplished may well place the country as the fulfilment centre of the world's pharma and healthcare needs.
Three IIMs to offer 5-year undergrad-to-MBA course
This year, at least three IIMs join the undergraduate education club. High school students would be picked and trained for intensive business education for five years.
Utkal Tubers plans to produce 30,000 metric tonne of seed potato by FY23
"Because we have been able to supply quality material in the market, demand for our product has risen significantly over the last 2 years. We are well on track to produce 30,000 metric tonne of seed potato including IPM varieties by FY23," Sanjay Mahant, CEO of Utkal Tubers told.
IIM Ranchi to offer 5-Year integrated programme in management from 2021
Students admitted to this program will get a longer duration to develop their practical leadership and managerial skills. They will be exposed to rigorous coursework that places equal importance on learning and development and student well-being.
Bigger money will be made in top 4 private banks over next 12 months: Aditya Khemani
'The market correction today is a part of overall profit-booking exercise.'
Godfrey Phillips rejects FDI norms violation allegations; says in complete compliance with law
Godfrey Phillips has an exclusive procurement and supply agreement with Philip Morris International to manufacture and distribute Marlboro in the country.
Philip Morris International appoints Alexander Reisch as IPM India Wholesale Trading MD
IPM India Wholesale Trading is a joint venture between Philip Morris Brands Sarl of Switzerland, Godfrey Phillips India and K.K. Modi Investment & Financial Services.
IIM Indore sees 10% jump in salary offers
Pre-placement offers at Indian Institute of Management, Indore, this year have seen an average 10% increase in salary package over the previous year.
Congress demands CBI probe of IPM bank scam in Chhattisgarh
Raising the issue in the question hour, state Congress chief Bhupesh Baghel asked whether the state government had recovered loans of Rs 1 crore or more sanctioned by the bank.
Maggi samples being tested in Telangana as part of nationwide drive
The testing is being done as part of the nationwide drive on the directives from the Central food safety body.
L&T buys British firm Thalest for Rs 24 crore
The acquisition of Thalest by L&T's electrical and automation business division is aimed at expanding the automation offerings for ships.
Load More
